Afatinib activity in uncommon EGFR mutation-positive lung cancer

Results from the first prospective data series on afatinib activity, the irreversible HER family blocker, in non-small-cell lung cancer patients with tumours harbouring uncommon EGFR mutations, were presented at Oral Abstract Session on Targeted Therapies during the 15th World Conference on Lung Cancer (27 - 30 October 2013, Sydney, Australia). Afatinib showed activity in tumours harbouring mutations, such as G719X, L861Q and S768I. Read more here.